ストックスクリーナーアプリを入手
4.64
34.10%
1.18
Humacyte Inc (HUMA) 最新ニュース
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $596,000 in Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, - GlobeNewswire
Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - AccessWire
Humacyte, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - AccessWire
Humacyte Receives FDA Approval for SYMVESS Launch - TipRanks
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL
FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine - Endpoints News
FDA approval propels North Carolina company's breakthrough treatment for trauma patients - The Business Journals
Humacyte’s tissue-engineered graft for vascular trauma approved by FDA - BioWorld Online
Shareholders That Lost Money on Humacyte, Inc. (HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - AccessWire
US FDA approves Humacyte’s Symvess for vascular trauma - Vascular News
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte Stock Hits Over 1-Month Highs On FDA Nod For Bioengineered Tissue In Treating Vascular Trauma, Retail - Asianet Newsable
Humacyte's (HUMA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Humacyte (NASDAQ:HUMA) Shares Gap UpHere's Why - MarketBeat
Spotlight on Humacyte: Analyzing the Surge in Options Activity - Benzinga
Huma Stock Surges Following FDA Approval of Groundbreaking Bioengineered Vascular Conduit - The Africa Logistics
BTIG reiterates Buy on Humacyte stock as FDA approval of SYMVESS boosts commercialization prospects - Investing.com South Africa
Humacyte's (HUMA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Humacyte's bioengineered human tissue gains FDA approval - FirstWord Pharma
Humacyte shares target raised, buy rating held on FDA approval - Investing.com
Humacyte surges on FDA approval for Symvess vascular repair product - MSN
Humacyte stock surges on Symvess FDA approval (HUMA:NASDAQ) - Seeking Alpha
Humacyte stock surges over 50% on FDA approval - Investing.com
Humacyte Shares Surge 38% on FDA Approval of Symvess - Marketscreener.com
Shareholders that lost money on Humacyte, Inc.(HUMA) Urged to Jo - GuruFocus.com
Shareholders that lost money on Humacyte, Inc.(HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - Morningstar
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone' - Benzinga
FDA Approves Humacyte's Groundbreaking Bioengineered Blood Vessel Treatment SYMVESS in Historic First - StockTitan
Humacyte's SYMVESS gets FDA nod for vascular trauma - Investing.com
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma - The Manila Times
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
Humacyte’s (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles – Hagens Berman - GlobeNewswire
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – HUMA - EIN News
Humacyte, Inc. Class Action Lawsuit Alert: Johnson Fistel - GlobeNewswire
Humacyte, Inc. (NASDAQ:HUMA) Holdings Boosted by Fmr LLC - Defense World
Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your RightsHUMA - PR Newswire
Investors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - AccessWire
Class Action Filed Against Humacyte, Inc. (HUMA)January 17, 2025 Deadline to JoinContact Levi & Korsinsky - AccessWire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. - EIN News
Individual investors who have a significant stake must be disappointed along with institutions after Humacyte, Inc.'s (NASDAQ:HUMA) market cap dropped by US$60m - Yahoo Finance
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - PR Newswire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Humacyte, Inc. Investors of - EIN News
Humacyte's SWOT analysis: HAV tech stock shows promise amid safety concerns - Investing.com
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Humacyte, - GlobeNewswire
Humacyte (NASDAQ:HUMA) Stock Price Down 6.7%Time to Sell? - MarketBeat
Investors who lost money on Humacyte, Inc. (HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - AccessWire
Humacyte (NASDAQ:HUMAW) Shares Up 7.9% – What’s Next? - Defense World
Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 6.2% in November - MarketBeat
The Manufacturers Life Insurance Company Raises Position in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Newsfile
Humacyte, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before January 17, 2025 to Discuss Your RightsHUMA - Lelezard
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire
Investors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights – HUMA - GlobeNewswire
Investors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights – - EIN News
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for InvestorsContact Levi & Korsinsky - AccessWire
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Should Contact Levi & Korsinsky about Pending Class ActionHUMA - AccessWire
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - AccessWire
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):